Select Page
Projects

PHARMECO

Advancing safe and sustainable by design practices in pharmaceutical manufacturing

Budget
20.549.438,00 €
Duration
Start date:
01/11/2024
End date:
31/10/2030
Beneficiaries
AIMPLAS; UNIVERSITEIT GENT; UNIVERSITAET GRAZ; RESEARCH CENTER PHARMACEUTICAL ENGINEERING GMBH; CENTRE FOR PROCESS INNOVATION LIMITED LBG; RISE RESEARCH INSTITUTES OF SWEDEN AB; TECHNISCHE UNIVERSITAT BERLIN; Biotoolomics Limited; STICHTING RADBOUD UNIVERSITEIT; VTU; Engineering GmbH; LOUGHBOROUGH UNIVERSITY; CULTZYME SL; MICROINNOVA ENGINEERING GMBH; RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU; LifeClean International AB; BENKEI; SFE Process; RISE PROCESSUM AB; ABBVIE DEUTSCHLAND GMBH & CO KG; ASTRAZENECA UK LIMITED; AstraZeneca Pharmaceuticals LP; BOEHRINGER INGELHEIM INTERNATIONALGMBH; BOEHRINGER INGELHEIM PHARMA GMBH & CO KG; JANSSEN PHARMACEUTICA NV; SOFRADIM PRODUCTION SASU; NOVO NORDISK A/S; MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN; MERCK HEALTHCARE KGAA; MERCK ELECTRONICS KGAA; Ares Trading SA; Merck Life Science KGaA; MERCK SERONO SPA; Istituto di Ricerche Biomediche Antoine Marxer RBM S.p.A.; PFIZER INC; Pfizer Italia s.r.l.; PFIZER LIMITED; Pfizer R&D UK Limited; PFIZER IRELAND PHARMACEUTICALS; SANOFI-AVENTIS DEUTSCHLAND GMBH; Sanofi Winthrop Industrie SA; Sanofi; Sanofi Genzyme; SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT; ORIL INDUSTRIE; INSTITUT DE RECHERCHES INTERNATIONALES SERVIER IRIS; SwiftPharma BV; GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.; UCB BIOPHARMA; UCB Pharma B.V.; UCB BioSciences GmbH; UCB celltech pharmaceuticals; UCB Farchim
SDG

AIMPLAS is aligned in this project with the following Sustainable Development Goals (SDGs).

Objectives

  • Develop Sustainable-by-Design (SSbD) Platforms: Enhance early-stage pharmaceutical product development through SSbD-driven, process-intensified technologies like continuous manufacturing.
  • Design Eco-Friendly Manufacturing Processes: Create sustainable production systems for small molecules, peptides, oligonucleotides, proteins, and RNA with advanced control measures.
  • Scale-Up and Demonstrate Sustainable Manufacturing: Develop and demonstrate environmentally-friendly processes at an industrial scale, ready for GMP environments and clinical testing.
  • Implement Digital Decision-Making Tools: Create modular digital tools for evaluating and optimizing sustainability across pharmaceutical manufacturing processes.
  • Standardize Environmental Sustainability Assessments: Collaborate with stakeholders to establish robust guidelines and standardized Life Cycle Assessment (LCA) methodologies for the pharmaceutical industry.
  • Facilitate Regulatory Adoption of Sustainability Standards: Promote the adoption of standardized LCA practices within regulatory frameworks to enhance environmental compliance.
  • Integrate Sustainability Across the Entire Manufacturing Lifecycle: Ensure sustainability is embedded from the design phase to disposal, revolutionizing the pharmaceutical manufacturing industry.

Description

The uniqueness of PHARMECO relies on:
  1. the synergistic interconnection from modeling to upscaling in test setting to industrial scale,
  2. the implementation of a holistic end-to-end and integrated sustainability performance assessment considering also health gain,
  3. the introduction of prospective sustainability performance assessment, which will ensure sustainability and scalability of PHARMECO technologies and processes, that will be eligible to GMP (Good Manufacturing Practice) certification and finally
  4. the interdisciplinarity and the complementarity of the consortium will allow PHARMECO to address the full scope of the project.

Financing

funded by ue
Healthcare
Health
European
03. Salud y bienestar
09. Industria, innovación e infraestructura
12. Producción y consumo responsables
Catalysis
Polymer synthesis